:
Hypogonadotropic hypogonadism (HH) is caused by a dysfunction in the hypothalamus and/or the
pituitary gland and it can be congenital or acquired. This condition is biochemically characterized by low
or inappropriately normal gonadotropins levels along with low total testosterone levels. If fertility is not
an issue, testosterone therapy is the treatment of choice to induce and maintain secondary sexual
characteristics and sexual function. Spermatogenesis is frequently impaired in patients with HH, but
usually responsive to hormonal therapy such as gonadotropin therapy or GnRH
supplementary/replacement therapy. When gonadotropins are the choice of treatment conventional
therapy includes human chorionic gonadotropin (hCG) along with different FSH formulation: human
menopausal gonadotropins (hMG), highly purified urinary FSH preparations (hpFSH) (e.g.,
urofollitropin) or recombinant FSH (rFSH). The combination of FSH and hCG demonstrated to be
associated with better outcomes than single compounds, whereas similar results were obtained with
different FSH preparations in male individuals both regarding the ability to stimulate spermatogenesis
and eventually inducing physiology pregnancy. Gonadotropins can be administered either subcutaneously
or intramuscularly. The combination therapy with hCG and FSH for a period of 12-24 months was found
to promote testicular growth in almost all patients, spermatogenesis in approximately 80% and pregnancy
rates in the range of 50%. Gynecomastia is the most common side effect of gonadotropin therapy and is
due to hCG stimulation of aromatase causing increased secretion of estradiol. The therapeutic success is
higher in patients with post-puberal HH, in those without previously undescended testes, in patients with
higher baseline testicular volume, who underwent repeated cycles of therapy and in patients with higher
baseline inhibin B serum concentrations. Reversal of hypogonadism can occur in up to 10% of patients
but its physiophatologic mechanism has yet to be elucidated. In conclusion, gonadotropins therapy is
effective in promoting puberty and in supporting spermatogenesis onset and preservation in HH patients
with either hypothalamic or pituitary conditions.